�
Eden Research Plc
("Eden" or "Company")
�
Posting of Annual Report & Notice of AGM
�
Eden Research plc (AIM: EDEN), the AIM-listed company that provides breakthrough natural bio-control products and microencapsulation technologies to the global agrochemicals, animal health and consumer products industries, announces that its Annual Report and Accounts for the year ended 31 December 2016, Notice of the Annual General Meeting ("AGM") and a Form of Proxy have been posted to shareholders and are now available on the Company's website: www.edenresearch.com �
�
The AGM is to be held on Friday 30 June 2017 at 12.00pm at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED. �
�
�
|
Eden Research plc ��������� |
|
|
Sean Smith, Chief Executive Officer |
Tel: 01285 359 555 |
|
Alex Abrey, Chief Financial Officer |
|
|
|
|
|
Shore Capital and Corporate Limited����� |
|
|
Stephane Auton/Patrick Castle |
Tel: 020 7408 4090 |
|
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or [email protected] |
|
Paul McManus |
Mob: 07980 541 893 |
|
Lianne Cawthorne |
Mob: 07584 391 303 |
�
Notes:
Eden � Research is a technology development and commercialisation company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions for the global agrochemicals, animal health, and consumer product industries.
�
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. The technology uses yeast cells that are a by-product of numerous commercial production processes to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetics and pharmaceutical industries.
�
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
�
Eden is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
�
The Company has a number of patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of �12m in developing and protecting its intellectual property and seeking regulatory approval for products that rely upon the Company's technologies. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, gaining regulatory approvals, identifying suitable industrial partners, and entering into commercial agreements.��
�
In May 2013, the three actives that comprise Eden's first commercial product, 3AEY, were approved as new ingredients for use in plant protection products. This represented a major milestone in the commercialisation of Eden's technology and is a significant accomplishment for any company.��To illustrate this point, one should note � that in all of 2013, Eden's approvals represented 3 of only 10 new active ingredients approved by the EC.
�
�
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.
�
For more information about Eden, please visit:� www.edenresearch.com
�
�